Chuck Conroy Appointed CEO of ARTMS

September 10, 2019 CPDC

VANCOUVER, British Columbia–ARTMS Products Inc., the global leader in the innovation and commercialization of novel technologies that enable cyclotron production of the world’s most needed medical radioisotopes, is pleased to announce the appointment of Charles S. Conroy R.Ph, MBA as its Chief Executive Officer.

Mr. Conroy brings to ARTMS more than 25 years of experience in the life sciences industry, including several significant senior positions within the radiopharmaceutical industry. Most recently Mr. Conroy was the General Manager of Jubilant Pharma where he was responsible for North American sales and operations. Prior to joining Jubilant, he was the Chief Operating Officer of PharmBlue LLC and has held leadership roles in various life sciences companies including Express Scripts, United BioSource Corporation, Covidien and Eli Lilly.

“I am excited to embark on this new journey as CEO of ARTMS, leading an exceptional organization, and expanding the commercialization of its innovative technology for the production of critical medical isotopes”, said Mr. Conroy. “ARTMS’ award-winning technology has the potential to revolutionize the nuclear medicine industry by enabling global access to cyclotron-produced medical isotopes. I look forward to building upon the company’s current successes and accelerating its growth.”

“We are very pleased to welcome Chuck Conroy as our new CEO. Chuck is a remarkable leader with an impressive track record of building marketing and sales strategies and comes with a wealth of experience scaling life sciences companies” said Steven Foster, Chairman of the Board of ARTMS. Mr. Conroy replaces Interim CEO, Dr. Kaley Wilson.

Mr. Conroy joins ARTMS at an exciting time in the expansion of the commercialization of the ARTMS QUANTM Irradiation System™. The QIS™ technology was developed in collaboration with scientists and clinical researchers from TRIUMF, BC Cancer, the Centre for Probe Development and Commercialization, and Lawson Health Research Institute and has already been deployed within a number of different OEM cyclotrons in major markets, including North America, Europe and Asia. It is a hardware and consumable system that provides for cost-effective, decentralized, and local production of important medical isotopes, including technetium-99m, gallium-68, zirconium-89 and copper-64. Having already proven the concept and clinical application for routine and high-yield production of technetium-99m, ARTMS continues to drive a paradigm shift from the current supply chain model and is moving into advanced commercialization of cyclotron-produced gallium-68, a much sought after and valuable isotope for medical imaging in prostate and neuroendocrine tumours.

In addition, ARTMS also announced that Mr. Len Ducker will join the Board of Directors of ARTMS. Mr. Foster remarked, “Len’s deep knowledge of radiopharmaceuticals and molecular imaging and 35 years experience with GE Healthcare will be a valuable asset to the ARTMS Board. I look forward to him joining us on the Board.”

About ARTMS
Based in Vancouver, British Columbia, ARTMS Products Inc. is a leader in the development of novel technologies and products which enable the production of the world’s most-used diagnostic imaging isotope, technetium‐99m (Tc‐99m), using local, hospital-based medical cyclotrons. In addition to Tc-99m, ARTMS has developed advanced solutions for the supply of gallium-68 (Ga-68), zirconium-89 (Zr-89) and copper-64 (Cu-64). ARTMS holds the exclusive global commercialization rights to award-winning and proprietary Canadian inventions which address these challenges, and which offer the prospect of revolutionizing the nuclear medicine industry.

For more information on the QUANTM Irradiation System™ and ARTMS Products, please follow us on Twitter @Quantm99 and LinkedIn and visit http://www.artms.ca/

View source version on businesswire.com:
https://www.businesswire.com/news/home/20190910005187/en/

Contacts

PR Associates
Kamran Shaikh, 778-846-5406
kshaikh@prassociates.com 

Centre for Probe Development and Commercialization
Angela Laurentani, 905 525-9140, ext. 21212
cpdc@imagingprobes.ca

More news from CPDC

Study gives Ontario men access to advanced prostate cancer imaging

LONDON, Ontario – Led by researchers at Lawson Health Research Institute, a multi-centre registry trial is testing the use of a new imaging tracer, called a PSMA tracer, for early detection of recurrent prostate cancer. The registry gives patients access to a new type of imaging and will assess the impact on patient care. PSMA

ARTMS Products Received $1.5 Million of Funding from the Federal Government

VANCOUVER, British Columbia–ARTMS Products Inc., a global leader in the development and commercialization of novel technologies and products that enable cyclotron production of the world’s most needed medical radioisotopes, is pleased to announce they have received $1.5 million funding from Western Economic Diversification Canada as part of its Business Scale-up and Productivity program. The federal

CPDC Celebrates Successful FDA Inspection!

Hamilton, Ontario, August 16, 2019 – The Centre for Probe Development and Commercialization’s Senior Leadership Team took time on Friday afternoon to celebrate with their Hamilton staff on the McMaster University campus at the famous Willy Dog Hot Dog cart. Over 60 staff attended the lunch time event on a great summer day!  The event

For more information contact us at: